AUTHOR INDEX

Adelstein, A., 7
Alter, M., 225

Barbujani, G., 239
Barnwell, G. M., 101
Baskerville, J. C., 45
Beral, V., 7
Bingham, S. F., 435
Blackburn, H., 401
Bonadonna, G., 333
Brown, B. W., Jr., 307
Buzdar, A., 333
Byar, D. P., 361

Califf, R. M., 143, 375
Calzolari, E., 239
Canner, P., 423
Chen, R., 173
Chuang, C., 273
Collins, J. F., 435
Collins, R., 409
Cox, C., 273
Crowder, M., 165

DeMets, D. L., 445
Detre, K. M., 389
Diamond, J. J., 353
Donner, A., 199

Feinstein, A. R., 341
Forbes, J. F., 249
Friedman, L., 305

Gardner, M. J., 113
Gehan, E., 225, 315
Gilson, J. C., 73
Goldman, A. I., 153
Green, S. B., 361
Greenland, S., 131

Hadgu, A., 293
Harrell, F. E., Jr., 143, 375
Higgins, I. T. T., 73
Hlatky, M. A., 375
Hoehler, F. K., 225
Hoitsma, A. J., 219
Hook, E. B., 287

Inskip, H., 7

Jennings, B., 45
Jones, R. N., 73
Jones, S. E., 333

Kahana, E., 225
Keselman, H. J., 185
Keselman, J. C., 185
Kimber, H., 165
Klett, C. J., 435
Klingberg, M. A., 173
Koene, R. A. P., 219
Kramer, S., 353

Landis, J. R., 73
Lee, K. L., 143, 375
Lilienfeld, D. E., 15
Louis, T. A., 1

Makuch, R. W., 35
Mantel, N., 173, 225
Marinez, Y. N., 101
Mark, D. B., 375
Mazza, J., 45
McDowall, M., 7
McHugh, R., 215
McMahan, C. A., 101
Meier, P., 473
Moertel, C. G., 455
Montague, E., 333
Moon, T. E., 333

Moses, L., 1
Musch, D. C., 73

Newnham, P., 85

Osmond, C., 113

Peto, R., 409
Pickering, R. M., 249
Pinsky, C. M., 325
Powles, T. J., 333
Pryor, D. B., 143, 375
Pyne, D. A., 15

Regal, R. R., 287
Rivkin, S., 333
Roman, E., 7
Rosati, R. A., 143, 375
Rosenbaum, P. R., 27

Shirley, E. A. C., 85
Simon, R., 35. 305
Stoddard, A. M., 261
Sturt, E., 57

Toogood, J. H., 45

van Elteren, P., 219
van Lier, H. J. J., 219
Verter, J., 305

Weiss, D. G., 435
Wigodsky, H., 101
Williams, O. D., 469
Williford, W. O., 435
Wittes, J., 305
Wittes, R., 305

Yusuf, S., 409

Zelen, M., 399

STATISTICS IN MEDICINE, VOL. 3, 483–486 (1984)

SUBJECT INDEX

((L) indicates subject discussed in Letter to the Editors)

Age period cohort model, 113
Age-specific rates, 7, 113
Age standardization, 7, 113
Allocation, treatment, 219
  adaptive, 45
Analgesics, clinical trial of, 273
Analysis of covariance, 85
Analysis of variance, 85
Assessment of medical care, 353
Asthma, 45
Attributable fraction, 131
Attributable risk, 131
Automatic classification algorithm, 261

Base comparison logit models, 273
BCG, 325
Beta-blockade, clinical trials of, 409
Beta-blocker heart-attack trial (BHAT), 445
Bias, confounding, 131
Bias, selection, in historical control studies, 225, 315
  in single consent designs, 215
Bias, susceptibility, 341
Bias, time to response, 35
Birth defects, surveillance of, 239
Book Reviews
  N. T. J. Bailey, *The Biomathematics of Malaria*, 93
  M. E. Buyse, M. J. Staquet and R. J. Sylvester (Eds) *Cancer Clinical Trials: Methods and Practice*, 303
  W. H. Carter, G. L. Wampler and D. M. Stablein, *Regression Analysis of Survival Data in Cancer Chemotherapy*, 197
  V. Mike and K. E. Stanley (Eds) *Statistics in Medical Research: Methods and Issues, with Applications in Cancer Research*, 303

Caesarian section, 131
Cancer, bowel, 455
  breast, 333
  cervix, 113, 353, 359
  clinical trials, 314, 455
  colorectal, 455
  Hodgkin's disease, 173, 353, 359
  immunotherapy, 325
  leukemia, 325
  lung, 35, 113
  lymphoma, cutaneous, 361
  malignant melanoma, 325
  mycosis fungoides, 361
  not measurable, evaluable, 455
  osteogenic sarcoma, 455
  stomach, 455
Cancer—*contd.*
  surgical adjuvant therapy, 455
  testis, 113, 153
  thyroid, 361
Cancer Registry data, 361, 371
Cardiac transplantation, 35
Cardiovascular disease, 331
  database, Duke University, 375
  epidemiology, 15
Care, assessment of medical, 353
Case-control studies, case definition in, 27
  power, 27
Case definition, 27
Cause-specific mortality ratio, 7
Censored observations, 35, 143, 153, 165, 199, 225
Chest radiography, 73
Chi-square partitioning, 273
Classification, automatic, 261
  latent class analysis, 249
Clinical research, evolutionary programme, 315
  statistical consultation in, 1
Clinical trials, 225, 305–475
  allocation of treatment, 45, 219
  analgesics, 273
  asthma, 45
  beta-blockade, 409, 445
  breast cancer, 333
  cancer, 315, 455
  consent designs, randomized, 215
  costs, 409, 423, 433, 469, 473
  cross-over designs, 45, 199
  cross-protocol comparisons, 333
  data monitoring committee, 445, 453
  data quality control, 101, 423, 469
  design, 199, 409, 435
  drop-out, 199, 435
  early termination, 445, 453, 469
  efficiency, 455, 473
  eligibility criteria, 421
  ethics, 315
  generalizability, 307, 313
  group sequential design, 445
  intention to treat, 341, 347, 371, 409, 467
  interaction in analysis, 409
  inter-trial comparisons, 333
  limitations, 307, 375
  myocardial infarction, 409, 423
  non-randomized controls, 225, 341
  phase II studies, 467
  pilot studies, 435
  planning, 435
  power, 45, 199, 409

Clinical trials—*contd.*
quality of data collection, 101, 423, 469
randomization, 199, 341, 347, 385, 409, 467
recruitment rate, 435, 469
repeated measures design, 185
replication, 307
size, 45, 199, 315, 409, 435
stochastic curtailing, 445
strengths, 307
therapeutic preferences, 45
treatment allocation, 45, 219
Zelen's single consent design, 215
Closed population size, confidence interval for, 287
Clustering, space–time, 173
variable, 143
Cohort studies, 401
Collaboration between clinician and statistician, 1
Comparative cohort mortality figure, 113
Comparative mortality figure, 113
Comparisons, cross-protocol, 333
Confidence interval for closed population, 287
Confirmatory studies, 405
Congenital malformation, 239
Congenital syphilis, 293
Consent designs for clinical trials, 215
Consultation, statistical, 1
Continuation ratios, 273
Contrasts, tests of in repeated measures designs, 185
Coronary artery disease, 143, 375, 389
Surgery Study (CASS), 375
Coronary Drug Project (CDP), 423, 445
Costs, of clinical trials, 409, 423, 433, 469, 473
of data collection, 423
Covariance, analysis of, 85
Covariate, time-dependent, 35
Cox regression model, 143, 225
Cross-over clinical trials, 45, 199
Cumulative odds logit model, 273
Cure model in survival analysis, 153
Cusum techniques, 239

Data collection, 101, 423, 469
Data editing, 101
Data management system, 101
Data monitoring committee, 445, 453
Data quality control, 101, 423, 469
Database, 333, 375, 385, 405
cardiovascular disease, 375
Death rate, crude, 113
standardized, 113
Decision tree for pattern classification, 261
Diabetic Retinopathy Study, 445
Disease, inherited, 57

ECG reading, 423
Editorial, Statistical guidelines for medical journals, 97
Efficacy of treatment, 45, 305–475
Efficiency of clinical trials, 455, 473
Eligibility criteria for clinical trials, 421
EM algorithm, 249
Epidemic models, 165
Epidemicity of Hodgkin's disease, 173
Epidemiology, 7, 15, 27, 73, 113, 131, 173
cardiovascular, 15
Ethics of clinical trials, 315
of historical control studies, 315
of treatment, 385
Evaluation of therapy, proceedings of workshop, 305–475
Evolutionary research programme, 315
Expected mortality, calculation of, 301(L)

Foetal monitoring, 131

Genetic marker association, 57
Genetics, human, 57
Goodness-of-fit based confidence intervals, 287
Graphical presentation of survival data, 35
Greenhouse–Geisser procedure, 185
Group randomization, 199
Group sequential designs for clinical trials, 445
Guaranteed survival, 225
Guidelines, statistical, for medical journals, 97

Hazard function, 153
Hazard rate, 301(L)
Heart transplantation, 35
Hereditary disease, 57
Historical control studies, 225, 315, 325, 331, 341, 361, 389, 401, 455
cancer immunotherapy, 325
ethics, 315
limitations, 315
medical registers, 225, 361, 389
prognostic factors, 225, 341, 361
selection bias, 225, 315
size, 315
standards for, 315
strengths, 315
Hodgkin's disease, 173, 353, 359
Human genetics, 57

Immunotherapy, 325
Infarct Survival, International Study of (ISIS), 409
Infectious diseases, models of, 165
Inherited disease, 57
Inosiplex, 225
Intention to treat, clinical trials of, 341, 347, 371, 409, 467
Interaction, scientific, between clinician and statistician, 1
Interactions in clinical trial analysis, 409
Inter-observer variation, 73
Inter-rate agreement, 73
Ischaemic attacks trial, Transient (TIA), 409

Kappa statistics, 73
Kidney transplantation, 219

Latent class analysis, 249
Linkage analysis, 57
Log-linear models, 287
Logistic model, 165
Logistic regression, 15
Logit models, 273

Marker association, genetic, 57
Medical journals, statistics in, 97
Medical registers, 225, 361, 371, 389
Microcephalia, 27
Model, age-period-cohort, 113
  Cox regression, 143, 225
  cure, in survival analysis, 153
  epidemic, 165
  infectious disease, 165
  linkage analysis, 57
  log-linear, 287
  logistic, 165
  logit, 273
  prognostic, 143
  regression, 143
Model validation, 143
Monitoring committee, data, 445, 453
Monitoring, foetal, 131
Monte Carlo simulation, 15, 85, 153, 173, 239
Morbidity ratio, standardized, 131
Mortality, calculation of expected, 301(L)
  occupational, 7
Mortality ratio, cause specific, proportional, 7
  standardized, 7
Multicollinearity, 293
Multiple comparison tests in repeated measures designs, 185
Multistate survival analysis, 35
Multivariate classification, 249
Myocardial infarction, clinical trials of, 409, 423

National Cancer Institute, U.S., 305
National Heart, Lung and Blood Institute, U.S., 305
Neonatal discharge record, 249
Non-randomized studies, 225, 341, 389

Observational database, 375
Observational studies, 341, 347, 361, 385, 399, 401, 405
  limitations of, 361
Occupational mortality, 7
Organ weights in toxicology, 85

Pain assessment data, ordinal, 273
Panencephalitis, 225
Partitioning chi-square, 273
Patient care, assessment of, 353
Patterns of care study (PCS), 353
Patterns of patient care, 353, 359
Phenotype classification, 261
Pilot studies for clinical trials, 435
Planning of research, 1, 315
Pneumoconiosis, 73
Population size, closed, 287
Power, case-control studies, 27
  clinical trials, 45, 199, 409
Prediction variable clustering, 143
Principal components regression, 143, 293
Proceedings of Workshop on Evaluation of Therapy, 305–475
Prognostic factors, 143, 219, 225, 333, 361, 375, 421
Prognostic model, 143
Prophylactic therapy, 341
Proportional mortality ratio, 7
Prospective studies, logistic analysis, 15

Quality control, data, 101, 423, 469
Quality of patient care, 353

Radiation therapy, 353
Radiography, chest, 73
Randomization, 199, 341, 347, 385, 409, 467
Randomization therapy, 215
Randomized block design, 185
Randomized clinical trials, *see* Clinical trials
Randomized consent design, 215
Rates, adjusted, 7
  age-specific, 7, 113
  comparison of, 119
  mortality, 7
Ratio, continuation, 273
  proportional mortality, 7
  standardized mortality, 7
Refereeing, 97
Registers, medical, 225, 361, 371, 389
Registry data, 361, 389
Regression, Cox, 143, 225
  logistic, 15
  models, 143
  principal components, 143, 293
  ridge, 293
  stepwise variable selection, 143
Relative risk, 27, 131, 199
Remedial therapy, 341
Renal transplantation, 219
Repeated measures design, 185
Research design, data management systems, 101
Research planning, 1
Research programme, evolutionary, 315
Resistance time to infection, 165
Retrospective therapy assessment, 353
Ridge regression, 293
Risk factors, 15, 131

Sample size, case-control studies, 27
  clinical trials, 45, 199, 315, 409, 435

Sample size—*contd.*
cure model survival analysis, 153
historical control studies, 315
Scientific interaction between clinician and statistician, 1
Selection bias, historical control studies, 225, 315
single consent designs, 215
Sensitivity of surveillance systems, 239
time–space clustering techniques, 173
Serum antitrypsin, 261
Serum cholesterol, 423
Set surveillance techniques, 239
Simpson's paradox, 361
Size, case-control studies, 27
clinical trials, 45, 199, 315, 409, 435
closed population, 287
historical control studies, 315
Space–time clustering, 173
Specificity of surveillance systems, 239
Sphericity, 185
Spina bifida, 287
Standardization, 7, 113
Standardized cohort mortality ratio, 113
morbidity ratio, 113
mortality ratio, 7, 113
Statistical consultation, 1
Statistical guidelines, 97
Statistics in medical journals, 97
Surveillance systems, 239
Survival, guaranteed, 225
Survival analysis, 35, 143, 153, 165, 199, 225
cure model, 153
graphical presentation, 35
multistate, 35
Survival function, 35
Syphilis, 293

Taconite workers, 73
Tests, contrast in repeated measures design, 185
Therapeutic preferences, clinical trials of, 45
Therapy, evaluation of, 305–475
prophylactic, 341
remedial, 341
Time to response bias, 35
Time-dependent covariate, 35
Time-space clustering, 173
Toxicology, 85
Transient state analysis, 35
Transplantation, 399
heart, 35
kidney, 219
Treatment allocation, 45, 219
Treatment dilution, in single consent designs, 215
Treatment efficacy, 45, 305–475
Trends in disease rates, 113

Variable selection, step-wise, 143
Variance, analysis of, 85
Variation, inter-observer, 73
Veterans Administration Cooperative Studies Program, 435

Walker–Duncan estimates, 15
Whooping cough, 165
Workshop on Evaluation of Therapy, preface, 305
proceedings, 305–475
speakers and discussants, 477

Zelen's single consent design, 215

CONTENTS

Volume 3, Issue Nos. 1–4

STATISTICS IN MEDICINE

Issue No. 1, January–March 1984

Statistical Consulting in Clinical Research: The Two-Way Street 1
L. Moses and T. A. Louis

A Comparison of Standardized and Proportional Mortality Ratios 7
E. Roman, V. Beral, H. Inskip, M. McDowall and A. Adelstein

The Logistic Analysis of Epidemiologic Prospective Studies: Investigation by Simulation 15
D. E. Lilienfeld and D. A. Pyne

Case Definition and Power in Case-Control Studies 27
P. R. Rosenbaum

A Non-Parametric Graphical Representation of the Relationship Between Survival and the Occurrence of an Event: Application to Responder Versus Non-Responder Bias 35
R. Simon and R. W. Makuch

Clinical Trials Designed to Evaluate Therapeutic Preferences 45
J. C. Baskerville, J. H. Toogood, J. Mazza and B. Jennings

Analysis of Linkage and Association for Diseases of Genetic Aetiology 57
E. Sturt

An Application of Kappa-Type Analyses to Interobserver Variation in Classifying Chest Radiographs for Pneumoconiosis 73
D. C. Musch, J. R. Landis, I. T. T. Higgins, J. C. Gilson and R. N. Jones

The Choice Between Analysis of Variance and Analysis of Covariance with Special Reference to the Analysis of Organ Weights in Toxicology Studies 85
E. A. C. Shirley and P. Newnham

BOOK REVIEW 93

Issue No. 2, April–June 1984

Editorial 97

Ensuring Data Quality in Medical Research Through an Integrated Data Management System 101
Y. N. Marinez, C. A. McMahan, G. M. Barnwell and H. Wigodsky

Interpretation of Time Trends in Disease Rates in the Presence of Generation Effects 113
M. J. Gardner and C. Osmond

Indexed or abstracted by 'Current Contents' and other leading Indexing/Abstracting Services.

Bias in Methods for Deriving Standardized Morbidity Ratio and Attributable Fraction Estimates 131
S. Greenland

Regression Modelling Strategies for Improved Prognostic Prediction 143
F. E. Harrell, Jr., K. L. Lee, R. M. Califf, D. B. Pryor and R. A. Rosati

Survivorship Analysis When Cure is a Possibility: A Monte Carlo Study 153
A. I. Goldman

An Analysis of Resistance Times to Infection Under Treatment 165
H. Kimber and M. Crowder

A Study of Three Techniques for Time–Space Clustering in Hodgkin's Disease 173
R. Chen, N. Mantel and M. A. Klingberg

The Analysis of Repeated Measures Designs in Medical Research 185
H. J. Keselman and J. C. Keselman

BOOK REVIEW 197

Issue No. 3, July–September 1984

Approaches to Sample Size Estimation in the Design of Clinical Trials—A Review 199
A. Donner

Validity and Treatment Dilution in Zelen's Single Consent Design 215
R. McHugh

Allocation of Treatment to Patients when not all Balancing Factors are Known to the Co-ordinating Centre 219
H. J. J. van Lier, P. van Elteren, A. J. Hoitsma and R. A. P. Koene

Medical Registers as Historical Controls: Analysis of an Open Clinical Trial of Inosiplex in Subacute Sclerosing Panencephalitis 225
F. K. Hoehler, N. Mantel, E. Gehan, E. Kahana and M. Alter

Comparison of Two Statistical Techniques for the Surveillance of Birth Defects Through a Monte Carlo Simulation 239
G. Barbujani and E. Calzolari

A Classification of Scottish Infants Using Latent Class Analysis 249
R. M. Pickering and J. F. Forbes

Automatic Classification of Biomedical Information when Classification Error is Unknown 261
A. M. Stoddard

A Comparison of Chi-square partitioning and Two Logit Analyses of Ordinal Pain Data from a Pharmaceutical Study 273
C. Cox and C. Chuang

Goodness-of-fit Based Confidence Intervals for Estimates of the Size of a Closed Population 287
R. R. Regal and E. B. Hook

An Application of Ridge Regression Analysis in the Study of Syphilis Data 293
A. Hadgu

LETTER TO THE EDITOR 301

BOOK REVIEWS 303

Issue No. 4, October–December 1984

PROCEEDINGS OF THE WORKSHOP ON EVALUATION OF THERAPY, SEPTEMBER 1983

Sponsored by the National Cancer Institute and the National Heart, Lung, and Blood Institute, Bethesda, MD 20205, U.S.A.

Preface 305
L. Friedman, R. Simon, J. Verter, J. Wittes and R. Wittes

The Randomized Clinical Trial 307
B. W. Brown, Jr.

Discussion 313

The Evaluation of Therapies: Historical Control Studies 315
E. A. Gehan

Experience with Historical Control Studies in Cancer Immunotherapy 325
C. M. Pinsky

Discussion 331

Using a Database of Protocol Studies to Evaluate Therapy: A Breast Cancer Example 333
T. E. Moon, S. E. Jones, G. Bonadonna, T. J. Powles, S. Rivkin, A. Buzdar and E. Montague

The Role of Observational Studies in the Evaluation of Therapy 341
A. R. Feinstein

Discussion 347

The Patterns of Care Study in Clinical Radiation Therapy—A Retrospective Assessment of Quality of Care 353
S. Kramer and J. J. Diamond

Discussion 359

Using Observational Data From Registries to Compare Treatments: The Fallacy of Omnimetrics 361
S. B. Green and D. P. Byar

Discussion 371

Tying Clinical Research to Patient Care by Use of an Observational Database 375
M. A. Hlatky, K. L. Lee, F. E. Harrell, Jr., R. M. Califf, D. B. Pryor, D. B. Mark and R. A. Rosati

Discussion 385

Non-randomized Studies of Coronary Artery Bypass Surgery 389
K. M. Detre

Commentary 399
M. Zelen

Commentary: Observation versus Experiment 401
H. Blackburn

Discussion 405

Why Do We Need Large, Simple Randomized Trials? 409
S. Yusuf, R. Collins and R. Peto

Discussion 421

How Much Data Should be Collected in a Clinical Trial? Experience of the Coronary Drug Project 423
P. Canner

Discussion 433

Planning Patient Recruitment: Fantasy and Reality 435
J. F. Collins, W. O. Williford, D. G. Weiss, S. F. Bingham and C. J. Klett

Can Early Stopping Procedures Impact Significantly on the Efficiency of Clinical Trials Without Serious Loss of Information 445
D. L. DeMets

Discussion 453

Improving the Efficiency of Clinical Trials: A Medical Perspective 455
C. G. Moertel

Discussion 467

Commentary 469
O. D. Williams

Commentary 473
P. Meier

List of Speakers and Discussants 477

Announcement 479

Author Index 481

Subject Index 483